Vincera Pharma Announces Name Change to Vincerx
Vincerx, a biopharmaceutical company focused on cancer therapeutics, announced a corporate name change from Vincera Pharma to Vincerx, Inc. on January 7, 2021. The ticker symbols for its common stock, units, and warrants will remain unchanged as 'VINC', 'VINCW', and 'VINCU'. Vincerx aims to address unmet medical needs in cancer treatment through innovative therapies and has a pipeline of products developed under a license agreement with Bayer, including clinical-stage and preclinical programs.
- Corporate name change to Vincerx, Inc. enhances branding.
- Continued trading under existing ticker symbols maintains stability.
- Strong pipeline stemming from exclusive agreement with Bayer.
- Neither financial metrics nor specific product development timelines were provided.
PALO ALTO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has changed its corporate name from Vincera Pharma, Inc. to Vincerx, Inc. The Company’s common stock, units and warrants will continue to trade under the current ticker symbols, “VINC,” “VINCW” and “VINCU,” respectively.
About Vincerx, Inc.
Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx’s executive team has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company intends to develop multiple products through clinical proof-of-concept and potentially through Accelerated Approval in the United States. For more information, please visit www.vincerx.com.
Cautionary Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to: Vincerx’s business model, pipeline, strategy and product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.
Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the potential effects of the COVID-19 pandemic; risks associated with preclinical or clinical development conducted prior to Vincerx’s in-licensing; failure to realize the anticipated benefits of the business combination, including as a result of difficulty in, or costs associated with, integrating the businesses of LSAC and Vincerx; failure to realize the benefits of the Bayer license; risks related to the rollout of Vincerx’s business and the timing of expected business milestones; changes in the assumptions underlying Vincerx’s expectations regarding its future business or business model; Vincerx’s ability to develop and commercialize product candidates; the availability and uses of capital; the effects of competition on Vincerx’s future business; and the risks and uncertainties set forth in LSAC’s definitive proxy statement on Schedule 14A filed with the SEC and reports on Forms 10-K, 10-Q and 8-K filed with or furnished to the SEC from time to time by LSAC or Vincerx. Forward -looking statements speak only as of the date hereof, and LSAC and Vincerx disclaim any obligation to update any forward-looking statements.
Contacts
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com
FAQ
What is the new name of Vincera Pharma?
What are the ticker symbols for Vincerx?
What is Vincerx's focus in the biopharmaceutical industry?
What is significant about the Bayer agreement for Vincerx?
When did Vincerx announce its name change?
